Iv Glow Bar
Los Angeles, CA, USA
Iv Glow Bar is an approved peptide clinic listing in Los Angeles. Services reference semaglutide, tirzepatide, bpc-157, cjc-1295, ipamorelin.
Semaglutide is associated with weight management pathways while sermorelin appears in hormone optimisation and longevity contexts. Use clinic profiles to compare service scope and clinician oversight.
Semaglutide and sermorelin typically appear in different clinical contexts — metabolic health versus hormone optimisation. If a clinic offers both, ask how each fits into its assessment model and monitoring plan. This page is for comparing provider approaches, not clinical suitability.
A GLP-1 receptor agonist used in weight management and metabolic health programmes.
A growth hormone–releasing hormone analogue listed in longevity and hormone optimisation clinics.
| Category | Semaglutide | Sermorelin |
|---|---|---|
| Directory context | Recovery / performance-focused listing context. | Weight / metabolic or longevity listing context. |
| Common goals | Recovery support, injury pathways, performance. | Weight management, metabolic health, longevity programs. |
| Guidance note | Informational listing only; suitability requires clinician review. | Informational listing only; suitability requires clinician review. |
Los Angeles, CA, USA
Iv Glow Bar is an approved peptide clinic listing in Los Angeles. Services reference semaglutide, tirzepatide, bpc-157, cjc-1295, ipamorelin.
USA, CA, USA
Wellness Club 365 is an approved peptide clinic listing in USA. Services reference semaglutide, tirzepatide, bpc-157, cjc-1295, ipamorelin, testosterone-therapy.
USA, CA, USA
Citrin Wellness is an approved peptide clinic listing in USA. Services reference semaglutide, tirzepatide.
USA, CA, USA
Gameday Men's Health North Hollywood TRT, Weight Loss, Peptides, and ED Clinic is an approved peptide clinic listing in USA. Services reference semaglutide, testosterone-therapy, tirzepatide.
These are often offered by different types of clinics. Choose based on your goal and the provider’s clinical governance rather than the peptide label.